Clinilabs Selected to Conduct a Phase I Clinical Trial of an Investigational New Drug for Insomnia
Clinilabs Inc announced that they have been selected to conduct a Phase I clinical trial of an investigational new drug for insomnia. The study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in a group of healthy, normal subjects and in otherwise healthy subjects who suffer from primary insomnia.
The study will begin to look at dose response on certain polysomnographically-defined sleep parameters and wake-time functioning, compared to the effects of an FDA-approved insomnia drug and placebo in subjects with insomnia. President and CEO, Dr. Gary Zammit reaffirmed Clinilabs’ unique attributes that helped secure the award. He states: “Our core competencies in early phase trials and the development of sleep therapeutics have led the industry to consider us the leading CRO in the field of sleep medicine. There is no other organization with deeper therapeutic-area knowledge, more experience, or greater operational capacity in this field than Clinilabs.”
Enrollment for this study is expected to begin in October at which time healthy adult males and females, and those who have been diagnosed with primary insomnia, between the ages of 18 – 64 are encouraged to participate. Individuals in the New York City metro area who would like to participate can contact Clinilabs’ call center at 212-994-4567 to prequalify. Additional information may also be found by visiting www.clinilabs.com/insomnia.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
